Takuya Matsumoto


Affiliation: Kyushu University
Country: Japan


  1. Matsubara Y, Matsumoto T, Aoyagi Y, Tanaka S, Okadome J, Morisaki K, et al. Sarcopenia is a prognostic factor for overall survival in patients with critical limb ischemia. J Vasc Surg. 2015;61:945-50 pubmed publisher
    ..02; 95% CI, 1.90-13.7; P = .001). Our results suggest that sarcopenia is a prognostic factor for CLI patients. Exercise and nutritional interventions focusing on improving sarcopenia might be useful treatment options for CLI patients. ..
  2. Matsumoto T, Matsubara Y, Aoyagi Y, Matsuda D, Okadome J, Morisaki K, et al. Radial force measurement of endovascular stents: Influence of stent design and diameter. Vascular. 2016;24:171-6 pubmed publisher
    ..In clinical settings, an understanding of the mechanical characteristics, including radial force, is important in choosing a stent for each patient. ..
  3. Yoshiga R, Morisaki K, Matsubara Y, Yoshiya K, Inoue K, Matsuda D, et al. Emergency thoracic aortic stent grafting for acute complicated type B aortic dissection after a previous abdominal endovascular aneurysm repair. Surg Case Rep. 2015;1:99 pubmed publisher
    ..After the operation, the image views and the symptoms were improved. The state was still stable 6 months later. TEVAR for acute type B aortic dissection can become one of the effective treatments. ..
  4. Miyazaki Y, Furuyama T, Matsubara Y, Yoshiya K, Yoshiga R, Inoue K, et al. Thoracic endovascular aortic repair for complicated chronic type B aortic dissection in a patient on hemodialysis with recurrent ischemic colitis. Surg Case Rep. 2016;2:38 pubmed publisher
    ..We believe that TEVAR supplemented by a noncovered aortic stent is an effective treatment, even for highly chronic B-AD in dialysis patients. ..
  5. Tanaka S, Matsumoto T, Matsubara Y, Harada Y, Kyuragi R, Koga J, et al. BubR1 Insufficiency Results in Decreased Macrophage Proliferation and Attenuated Atherogenesis in Apolipoprotein E-Deficient Mice. J Am Heart Assoc. 2016;5: pubmed
    ..In vitro assays indicated that decreased BubR1 expression impaired proliferation, but not migration, of bone marrow-derived macrophages. BubR1 may represent a promising new target for regulating atherosclerosis. ..
  6. Matsubara Y, Matsumoto T, Inoue K, Matsuda D, Yoshiga R, Yoshiya K, et al. Sarcopenia is a risk factor for cardiovascular events experienced by patients with critical limb ischemia. J Vasc Surg. 2017;65:1390-1397 pubmed publisher
    ..Furthermore, SAPT but not dual antiplatelet therapy increased cardiovascular event-free survival in patients with sarcopenia. ..
  7. request reprint
    Matsumoto T, Iwasa K, Kyuragi R, Honma K, Guntani A, Ohmine T, et al. The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. Int Angiol. 2010;29:49-54 pubmed
    ..N(G),N(G)-dimethyl-L-arginine, nitrate ions, and flow-mediated vasodilatation. Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans. ..
  8. Kyuragi R, Matsumoto T, Harada Y, Saito S, Onimaru M, Nakatsu Y, et al. BubR1 insufficiency inhibits neointimal hyperplasia through impaired vascular smooth muscle cell proliferation in mice. Arterioscler Thromb Vasc Biol. 2015;35:341-7 pubmed publisher
    ..BubR1 may represent a new target molecule for treating pathological states of vascular remodeling, such as restenosis after angioplasty. ..
  9. Okadome J, Matsumoto T, Yoshiya K, Matsuda D, Tamada K, Onimaru M, et al. BubR1 insufficiency impairs angiogenesis in aging and in experimental critical limb ischemic mice. J Vasc Surg. 2018;68:576-586.e1 pubmed publisher
    ..05). BubR1 insufficiency impairs angiogenesis and results in limb loss in ischemic hind limbs. BubR1 may be a crucial angiogenic factor and might be beneficial for the treatment of limb ischemia. ..